South Korean biosimilars developer Samsung Bioepis and Israel’s Teva Pharmaceutical Industries have entered into a license, ...

Alzheimer’s disease could be diagnosed up to a decade earlier after the world’s biggest study of proteins is completed. The ...

A daily polypill was estimated to be cost-effective for primary CVD prevention among U.S. adults living in historically ...

Mr. Jones added, “Annexon is leading the development of first-in-kind upstream complement medicines with significant opportunities across neuroinflammatory diseases that have yet to be unlocked. I ...

Recently, an 80-year-old man in Ahmedabad tested positive for human metapneumovirus (hMPV), adding to the growing cases of ...

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

Tens of millions of pounds in investment is being provided by the group of firms which includes AstraZenecaa and Pfizer ...

Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...

Drugmakers have started 2025, implementing price hikes for 583 products within the first two days of the new year alone, ...

The institute originally began reviewing Lynparza in this setting in 2018 but ended its review due to lack of evidence.

A WOMAN’S breasts ballooned after receiving the Covid vaccine, in a rare case that scientists are calling a “Pfizer boob job” ...